CN114901812A - 使用环状dna将抗原特异性受体基因导入至t细胞基因组的方法 - Google Patents

使用环状dna将抗原特异性受体基因导入至t细胞基因组的方法 Download PDF

Info

Publication number
CN114901812A
CN114901812A CN202080090344.XA CN202080090344A CN114901812A CN 114901812 A CN114901812 A CN 114901812A CN 202080090344 A CN202080090344 A CN 202080090344A CN 114901812 A CN114901812 A CN 114901812A
Authority
CN
China
Prior art keywords
vector
nucleic acid
sequence
antigen receptor
nuclease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080090344.XA
Other languages
English (en)
Chinese (zh)
Inventor
一户辰夫
山本卓
佐久间哲史
本庶仁子
川濑孝和
西泽正俊
铃木隆二
马郡健太
佐藤宽之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hiroshima University
Repertoire Genesis Inc
Original Assignee
Hiroshima University
Repertoire Genesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hiroshima University, Repertoire Genesis Inc filed Critical Hiroshima University
Publication of CN114901812A publication Critical patent/CN114901812A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080090344.XA 2019-11-14 2020-11-13 使用环状dna将抗原特异性受体基因导入至t细胞基因组的方法 Pending CN114901812A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019206448 2019-11-14
JP2019-206448 2019-11-14
PCT/JP2020/042429 WO2021095847A1 (ja) 2019-11-14 2020-11-13 抗原特異的受容体遺伝子を環状dnaを用いてt細胞ゲノムに導入する方法

Publications (1)

Publication Number Publication Date
CN114901812A true CN114901812A (zh) 2022-08-12

Family

ID=75912989

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080090344.XA Pending CN114901812A (zh) 2019-11-14 2020-11-13 使用环状dna将抗原特异性受体基因导入至t细胞基因组的方法

Country Status (6)

Country Link
US (1) US20230250415A1 (cg-RX-API-DMAC7.html)
EP (1) EP4060038A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2021095847A1 (cg-RX-API-DMAC7.html)
CN (1) CN114901812A (cg-RX-API-DMAC7.html)
TW (1) TW202124718A (cg-RX-API-DMAC7.html)
WO (1) WO2021095847A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI921044B (zh) * 2025-02-12 2026-04-01 宏碁股份有限公司 以胺基酸與來源蛋白關係產生負樣本的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105683375A (zh) * 2013-11-06 2016-06-15 国立大学法人广岛大学 用于插入核酸的载体
WO2018025206A1 (en) * 2016-08-02 2018-02-08 Kyoto University Method for genome editing
WO2019073965A1 (ja) * 2017-10-10 2019-04-18 国立大学法人広島大学 エフェクターT細胞(Teff)抗原受容体を用いた抗原特異的制御性T細胞(Treg)の作出技術
WO2019073964A1 (ja) * 2017-10-10 2019-04-18 国立大学法人広島大学 Platinum TALENを用いたT細胞受容体の完全置換技術
WO2019084552A1 (en) * 2017-10-27 2019-05-02 The Regents Of The University Of California TARGETED REPLACEMENT OF ENDOGENIC T CELL RECEPTORS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59942B2 (ja) 1974-01-11 1984-01-09 株式会社日立製作所 ホウデンガタイオンゲンヨウデンゲン
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
GB201407852D0 (en) * 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
JP6246258B2 (ja) 2016-04-25 2017-12-13 国立大学法人広島大学 Dna結合ドメインを含むポリペプチド
JP7045643B2 (ja) 2018-05-28 2022-04-01 日本電気硝子株式会社 ガラス物品の製造方法及び製造装置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105683375A (zh) * 2013-11-06 2016-06-15 国立大学法人广岛大学 用于插入核酸的载体
WO2018025206A1 (en) * 2016-08-02 2018-02-08 Kyoto University Method for genome editing
WO2019073965A1 (ja) * 2017-10-10 2019-04-18 国立大学法人広島大学 エフェクターT細胞(Teff)抗原受容体を用いた抗原特異的制御性T細胞(Treg)の作出技術
WO2019073964A1 (ja) * 2017-10-10 2019-04-18 国立大学法人広島大学 Platinum TALENを用いたT細胞受容体の完全置換技術
WO2019084552A1 (en) * 2017-10-27 2019-05-02 The Regents Of The University Of California TARGETED REPLACEMENT OF ENDOGENIC T CELL RECEPTORS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
韩冰舟;张亚鸽;张博;: "基因组靶向敲入技术在模式动物中的发展与应用:以斑马鱼为例", 生命科学, no. 09 *

Also Published As

Publication number Publication date
WO2021095847A1 (ja) 2021-05-20
EP4060038A4 (en) 2024-07-10
TW202124718A (zh) 2021-07-01
US20230250415A1 (en) 2023-08-10
JPWO2021095847A1 (cg-RX-API-DMAC7.html) 2021-05-20
EP4060038A1 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
CN113272435B (zh) 在多个主要组织相容性复合体分子上受限的ny-eso-1特异性t细胞受体的组合物
CA2474161C (en) Concatemers of differentially expressed multiple genes
CN101768616B (zh) 含稳定聚合酶的反应化合物的干组合物
CA2474172C (en) A library of a collection of cells
AU2019368215B2 (en) Engineered enzymes
AU2019236288B2 (en) Methods and compositions for inducible expression of neurotrophic factors
RU2763170C2 (ru) Производство олигосахаридов человеческого молока в микроорганизмах-хозяевах с модифицированным импортом/экспортом
CA2683497C (en) .delta.8 desaturases and their use in making polyunsaturated fatty acids
KR102942447B1 (ko) 위스콧-알드리치(Wiskott-Aldrich) 증후군에 대한 조혈 줄기 세포-유전자 치료요법
KR102652494B1 (ko) 전장 t-세포 수용체 오픈 리딩 프레임의 신속한 조립 및 다양화를 위한 2-성분 벡터 라이브러리 시스템
CN110402085A (zh) 用于生物控制植物病原体的系统和方法
CN109689856A (zh) 用于海藻宿主细胞的CRISPR-Cas系统
US20040110174A1 (en) Concatemers of differentially expressed multiple genes
CN104152572B (zh) 同时检测三种链球菌的三重实时荧光pcr方法及试剂盒
CN113302303B (zh) 经修饰的丝状真菌宿主细胞
CN101883843A (zh) 破坏过氧化物酶体生物合成因子蛋白(pex)以改变含油真核生物中多不饱和脂肪酸和总脂质含量
CN114480153B (zh) 一种生产维生素a的酿酒酵母菌及其构建方法
CN109517846A (zh) 基于CRISPR/Cas9系统高通量构建棉花突变体库的方法
CN116670157A (zh) 用于抗淋病奈瑟球菌的疫苗接种的组合物和方法
KR102898438B1 (ko) 리소좀 축적병을 완화시키기 위한 렌티벡터-형질도입된 t-rapa 세포의 용도
US6537767B1 (en) Method for screening antimycotically active substances
CN111867637B (zh) 新ehv插入位点ul43
KR20230134524A (ko) 무장된 세네카 밸리 바이러스 종양용해 요법 조성물및 그의 방법
CN117147870B (zh) 一种基于双细胞系统的抗骨硬化蛋白抗体活性检测方法
KR102160215B1 (ko) 자일로스 이용능이 개선된 야로위아 리폴리티카 균주 및 이의 제조방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220812

WD01 Invention patent application deemed withdrawn after publication